DGAP-News: MeVis Medical Solutions AG / Key word(s): Interim Report/9-month figures
Weaker license business, but growing service business
Bremen, August 22, 2017 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for the first three quarters of fiscal year 2017 (reporting period: October 1, 2016 to June 30, 2017.
Sales generated in the third quarter of 2017 amounted to EUR 4,440 k, up 17 % compared to the same quarter in the previous year (EUR 3,795 k). The development support services provided to Hologic accounted for a substantial share of this increase. As a result, sales rose year on year to
Operating costs increased in the third quarter of 2017, as planned. Personnel expenses saw a sub-stantial 18 % increase on account of the stock options issued in 2013 and exercised in the second and third quarters of 2017. Cumulated for the first three quarters, this also corresponds to a rise of 18 %. At EUR 448 k (prev. year: EUR 474 k), other operating expenses remained constant year on year in the third quarter. Cumulated for the first three quarters, other operating expenses fell by 18 % year on year.
Depreciation and amortization came to EUR 959 k (down 29 % year on year, primarily due to lower scheduled write-downs on capitalized development costs), resulting in EBIT (earnings before interest and taxes) of EUR 5,327 k (up a significant 69 % on the previous year's figure of EUR 3,143 k) for the reporting period and a corresponding EBIT margin of 38 % (prev. year: 27 %).
The financial result improved year on year, from EUR -487 k to EUR -211 k. The earnings of the 51 % share in MeVis BreastCare GmbH & Co. KG, which is recognized at equity, was largely responsible for this.
The tax result stood at EUR -1,149 k. After-tax earnings consequently fell by EUR 1,725 k to EUR 3,967 k, which is equivalent to undiluted earn-ings per share of EUR 2.18 (prev. year: EUR 3.13).
"We are pleased about the strong performance in the third quarter and thus, the continuation of the positive trend of the first two quarters." said Mr. Kirchhoff, CEO of MeVis Medical Solutions AG. Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG, added: "We hold on to the forecast for the current fiscal year and expect a significant increase in sales to between EUR 17.0 million and EUR 17.5 million and an EBIT of between EUR 5.0 million and EUR 5.5 million."
The company's financial reports are available for download on the following website:
22.08.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||MeVis Medical Solutions AG|
|Phone:||+49 421 224 95 0|
|Fax:||+49 421 224 95 999|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|